查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924678

注射用高免疫球蛋白市场依适应症、给药途径、包装、最终用户、通路和应用划分－2026-2032年全球预测

Hyperimmune Globulin Injection Market by Indication, Route Of Administration, Packaging Type, End User, Distribution Channel, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，高免疫球蛋白注射剂市场价值将达到 13.2 亿美元，到 2026 年将成长至 14.4 亿美元，到 2032 年将达到 26.1 亿美元，年复合成长率为 10.21%。

关键市场统计数据
基准年 2025 13.2亿美元
预计年份：2026年 14.4亿美元
预测年份 2032 26.1亿美元
复合年增长率 (%) 10.21%

高免疫球蛋白注射液概述：涵盖临床应用、生产关键点以及医疗机构中相关人员的考虑因素

高免疫球蛋白注射剂是一种成熟的免疫疗法，用于在多种临床情况下提供被动免疫。这些产品由含有高效价特异性抗体的混合血浆製成，可用于预防和治疗，降低感染疾病的风险并治疗毒素介导的疾病。临床医生和采购团队重视其靶向中和活性和明确的临床应用案例，而生产商和监管机构则强调供体筛检、抗体效力和一致的生产控制，以确保其安全性和有效性。

从技术、监管和医疗服务角度来看，正在塑造高免疫球蛋白注射模式的关键变革

受科学进步、供应链现代化以及监管机构对产品一致性日益重视的推动，高免疫球蛋白注射剂的市场环境正经历着多项变革。供体筛检和抗体滴度测定技术的进步使得血浆样本的选择更加精准，从而改善了效价谱并降低了批次差异。同时，分离和病毒灭活技术的创新提高了产品的安全裕度，而模组化生产方式则有助于应对突发的需求。

评估2025年美国关税变化对血浆衍生治疗药物供应链韧性、筹资策略和分销经济性的累积影响

2025年实施的关税调整和贸易措施为本已复杂的血浆衍生治疗药物供应链带来了新的挑战。关税调整影响跨境血浆采购的经济效益、中间成分的流通以及成品生物製品的进口。这促使相关人员重新评估其筹资策略，优先考虑与地理分散的供应商建立合作关係，并考虑实施国内生产或区域供应模式，以减少海关相关的延误和成本波动。

详细的细分市场分析揭示了适应症、用途、给药途径、最终用户复杂性、通路和包装形式如何共同影响临床和营运决策。

细分市场层面的洞察揭示了临床应用、给药途径、终端用户特征和包装形式如何相互作用，从而影响需求模式和营运优先顺序。根据适应症的不同，白喉、乙型肝炎、狂犬病、呼吸道融合细胞病毒和破伤风等疾病的产品关键性各不相同，每种临床场景都对给药时间和效力提出了独特的要求，从而影响库存管理和临床通讯协定。在基于用途的分类中，预防性用药和治疗性用药的区别会影响给药频率、获取的紧迫性以及支付方的考虑。预防性用药方案强调可预测的供应，而治疗性用药则需要快速取得，以满足急性照护需求。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和结构差异将影响高免疫疗法的供应、监管和临床应用。

区域趋势正在影响美洲、欧洲、中东和非洲以及亚太地区的供应链、监管参与和应用模式。虽然美洲地区完善的血浆采集基础设施和一体化生产网路能够保障不间断的生产，但公立和私立医疗机构的区域需求模式和报销环境却存在差异。因此，美洲地区的相关人员往往致力于优化捐赠者招募策略和配送物流，以满足都市区遍远地区的医疗需求。

竞争格局分析，重点在于阐述血浆分馏公司、特种生技药品公司、契约製造和分销合作伙伴之间的策略差异化因素。

高免疫球蛋白领域的竞争动态反映了由血浆分馏公司、特种生技药品公司、契约製造和经销商组成的复杂生态系统。领先企业通常透过投资强大的捐血网路、检验的病毒灭活平台以及用于抗体滴度表征的先进分析技术来实现差异化。此外，能够整合从血浆采集到最终灌装和包装的端到端能力的公司往往能够更好地控制可追溯性和批次一致性。同时，专注于特定临床适应症的公司能够与医疗机构和公共卫生组织主导策略联盟。

为製造商、经销商和医疗保健提供者提供切实可行的建议，以增强韧性、调整临床准入并优化商业性执行。

产业领导者应采取一系列务实且优先的措施，以提高供应可靠性、临床可及性和商业性可行性。首先，透过将国内捐赠者计画与精心挑选的国际供应商结合，建构血浆来源冗余，同时透过投资于捐赠者维繫和抗体滴度优化，确保高品质的原料。其次，透过检验可靠的病毒灭活技术、加强批次级分析以及实施数位化品质体系，实现生产流程现代化，从而提高可追溯性并缩短产品放行週期。第三，使产品包装策略与医疗服务实际情况相符。评估多管瓶和单剂量管瓶包装方案在预期给药环境下的适用性，以减少废弃物并简化物流。

我们采用混合方法研究，结合关键相关人员访谈、二手技术审查和迭代同行检验，以确保研究结果的严谨性和透明度。

本调查方法采用混合方法，结合一手质性访谈、系统性二手文献综述和技术检验，以确保研究结果的实证性。一手研究包括对临床专家、生产品质经理、采购负责人和物流经理进行结构化访谈，以了解实际营运中的限制因素、临床决策驱动因素以及供应商谈判趋势。二级资讯来源包括同行评审的临床文献、监管指导文件、生产最佳实践标准以及公开的临床项目描述，用于阐释访谈结果并检验技术论点。

针对参与高免疫球蛋白治疗的相关人员，综合考虑临床重要性、营运要务和供应链韧性因素，得出策略性结论。

总之，高免疫球蛋白注射剂在现代治疗手段中占有重要的策略地位，它透过特异性抗体提供标靶被动免疫，进而发挥临床疗效。血浆选择和分离技术的进步、改变给药途径的医疗服务模式的演变以及监管机构对可追溯性的重视，正在共同重塑相关人员的优先事项。供应链韧性仍然是一项核心挑战，因为关税变化和区域基础设施差异凸显了多元化采购、区域生产策略和更强大的物流伙伴关係关係的重要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依适应症分類的高免疫球蛋白注射市场

  • 白喉
  • B型肝炎
  • 狂犬病
  • 呼吸道融合细胞病毒
  • 破伤风

9. 依给药途径分類的高免疫球蛋白注射剂市场

  • 肌肉内注射
  • 静脉注射

第十章 高免疫球蛋白注射液市场（依包装类型划分）

  • 多剂量管瓶
  • 单剂量管瓶

第十一章 以最终用户分類的高免疫球蛋白注射剂市场

  • 门诊治疗中心
  • 诊所
  • 家庭医疗保健
  • 医院
    • 私立医院
    • 公立医院

第十二章 高免疫球蛋白注射剂市场（依通路划分）

  • 离线
  • 在线的

第十三章 高免疫球蛋白注射剂市场依应用领域划分

  • 预防
  • 治疗

第十四章 各地区高免疫球蛋白注射市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 高免疫球蛋白注射剂市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国高免疫球蛋白注射剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国高免疫球蛋白注射市场

第十八章：中国高免疫球蛋白注射剂市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ADMA Biologics
  • Baxter International Inc.
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Behring
  • Emergent BioSolutions
  • Green Cross Corporation
  • Grifols
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kamada Pharmaceuticals
  • Kedrion Biopharma
  • LFB Group
  • Octapharma
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Product Code: MRR-7A380DA7C41C

The Hyperimmune Globulin Injection Market was valued at USD 1.32 billion in 2025 and is projected to grow to USD 1.44 billion in 2026, with a CAGR of 10.21%, reaching USD 2.61 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.32 billion
Estimated Year [2026] USD 1.44 billion
Forecast Year [2032] USD 2.61 billion
CAGR (%) 10.21%

Foundational overview of hyperimmune globulin injections covering clinical roles, manufacturing imperatives, and stakeholder considerations across healthcare settings

Hyperimmune globulin injections represent an established immunotherapy modality used to confer passive immunity in diverse clinical contexts. These products, derived from pooled plasma with high titers of specific antibodies, are applied across prophylactic and therapeutic indications to mitigate infectious disease risk and treat toxin-mediated conditions. Clinicians and procurement teams value their targeted neutralizing activity and defined clinical use cases, while manufacturers and regulators focus on donor screening, antibody potency, and consistent manufacturing controls to ensure safety and efficacy.

The manufacturing pathway for hyperimmune globulins integrates plasma collection, fractionation, plasma testing, virus inactivation/removal steps, and final formulation under stringent quality systems. As a result, supply reliability depends on robust plasma sourcing networks, capacity for validated viral clearance technologies, and facility compliance with current Good Manufacturing Practice. From a clinical perspective, therapeutic choice and administration hinge on indication specificity, route of administration, and patient comorbidity profiles. Consequently, stakeholders must balance clinical guidelines, logistical constraints, and evolving regulatory expectations when integrating hyperimmune globulin injections into care pathways.

Key transformative shifts shaping the hyperimmune globulin injection landscape from technological, regulatory, and care delivery perspectives

The landscape for hyperimmune globulin injections is undergoing several transformative shifts driven by scientific advances, supply chain modernization, and regulatory emphasis on product consistency. Advances in donor screening and antibody titering enable more precise selection of plasma units, improving potency profiles and reducing variability between production lots. At the same time, innovations in fractionation and viral inactivation technologies strengthen product safety margins, while modular manufacturing approaches support scalable responses to episodic demand.

Concurrently, health systems are recalibrating care delivery models that affect where and how hyperimmune globulins are administered, pushing some administrations toward ambulatory and home settings while hospitals preserve capacity for acute and complex treatments. Additionally, heightened regulatory scrutiny around traceability and batch-to-batch comparability has encouraged manufacturers to invest in enhanced quality control platforms and digital documentation systems. Taken together, these shifts raise expectations for predictable supply, clinical clarity of indication, and improved time-to-treatment workflows across the continuum of care.

Assessment of the cumulative implications of United States tariff revisions in 2025 on supply chain resilience, sourcing strategies, and distribution economics for plasma-derived therapeutics

The implementation of revised tariffs and trade measures in 2025 has layered new considerations onto an already complex supply chain for plasma-derived therapies. Tariff adjustments influence the economics of cross-border plasma procurement, movement of intermediary components, and the importation of finished biologic products. In practice, this drives stakeholders to reassess sourcing strategies, prioritize geographically diversified supplier relationships, and explore onshore manufacturing or regionalized supply models to mitigate customs-related delays and cost volatility.

Moreover, tariff-driven cost pressures prompt manufacturers and distributors to examine their logistics footprints, optimize inventory policies, and renegotiate contractual terms with suppliers and payers. Health systems and payers respond by scrutinizing procurement frameworks and considering alternative distribution pathways to preserve clinical access. While tariffs do not change clinical indications or scientific rationale for use, they do affect the affordability and accessibility calculus for institutions, especially those that rely heavily on imported products or centralized manufacturing located outside their region.

In-depth segmentation insights revealing how indication, application, administration route, end user complexity, distribution channel, and packaging format jointly influence clinical and operational decisions

Segment-level insights reveal how clinical application, administration route, end user dynamics, and packaging format interact to shape demand patterns and operational priorities. Based on indication, product relevance varies across diphtheria, hepatitis B, rabies, respiratory syncytial virus, and tetanus, with each clinical scenario imposing distinct timing and potency requirements that inform inventory management and clinical protocols. Based on application, the differentiation between prophylactic and therapeutic use influences dosing frequency, urgency of access, and payer considerations, with prophylactic programs emphasizing predictable supply and therapeutic use requiring rapid availability for acute care.

Based on route of administration, intramuscular and intravenous delivery pose divergent training, storage, and administration workflows; intramuscular injections typically align with outpatient and ambulatory settings, whereas intravenous administration concentrates demand in inpatient or specialized infusion sites. Based on end user, the granular heterogeneity among ambulatory care centers, clinics, home healthcare, and hospitals-and the further subdivisions such as physician offices and urgent care within ambulatory care centers, general and specialty clinics, home infusion and home nursing within home healthcare, and private and public hospitals-creates differentiated procurement cycles, cold chain needs, and billing pathways. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy each present distinct regulatory, dispensing, and logistics profiles that influence how products reach patients. Finally, based on packaging type, the choice between multi dose vial and single dose vial affects inventory turnover, wastage risk, and cold-chain handling protocols.

Regional dynamics and structural variations across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence supply, regulation, and clinical adoption of hyperimmune therapies

Regional dynamics shape supply chains, regulatory engagement, and adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established plasma collection infrastructures and integrated manufacturing networks support uninterrupted production, yet regional demand patterns and reimbursement environments differ between public and private healthcare providers. Consequently, stakeholders in the Americas often focus on optimizing donor recruitment strategies and distribution logistics to meet both urban and rural access needs.

Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with heterogeneous reimbursement systems and variable plasma sourcing capacity, prompting manufacturers to build flexible distribution networks and engage in targeted regulatory dialogue. In the Asia-Pacific region, rapid healthcare modernization, expanding ambulatory care capacity, and growing emphasis on local manufacturing investments are reshaping where and how hyperimmune globulins are produced and delivered. These regional trends influence partnership models, clinical adoption timelines, and the prioritization of investments in cold chain infrastructure and local regulatory support.

Competitive landscape intelligence highlighting the strategic differentiators among plasma fractionators, specialty biologics producers, contract manufacturers, and distribution partners

Competitive dynamics in the hyperimmune globulin space reflect a mix of plasma fractionators, specialty biologics manufacturers, contract manufacturing organizations, and distributors that together form a complex ecosystem. Leading players often differentiate through investments in donor network strength, validated viral inactivation platforms, and advanced analytics for antibody titer characterization. In addition, companies that integrate end-to-end capabilities-from plasma procurement to final fill-finish-tend to achieve greater control over traceability and lot consistency, while firms that specialize in niche clinical indications can command strategic partnerships with healthcare providers and public health agencies.

Collaboration between manufacturers and specialized logistics providers is increasingly important to maintain cold chain integrity and rapid distribution. Strategic alliances, licensing agreements, and targeted acquisitions are common mechanisms used to expand capacity, enter new geographic markets, or accelerate time-to-market for indication-specific products. At the same time, firms that cultivate strong regulatory expertise and transparent pharmacovigilance frameworks create competitive advantages in procurement negotiations and clinical adoption discussions with hospitals and payers.

Actionable recommendations for manufacturers, distributors, and healthcare providers to enhance resilience, align clinical access, and optimize commercial execution

Industry leaders should adopt a set of pragmatic, prioritized actions to strengthen supply reliability, clinical accessibility, and commercial viability. First, build redundancy in plasma sourcing by cultivating a mix of domestic donor programs and selective international suppliers, while investing in donor retention and antibody titer optimization to secure higher-quality input material. Second, modernize manufacturing practices by validating robust viral reduction technologies, enhancing batch-level analytics, and implementing digital quality systems that improve traceability and reduce release cycle times. Third, align product packaging strategy with care delivery realities by evaluating multi dose vial and single dose vial configurations against expected administration settings to reduce wastage and streamline logistics.

Additionally, engage proactively with payers and clinical leaders to clarify appropriate prophylactic versus therapeutic use cases and to design pragmatic access pathways for ambulatory and home healthcare settings. Finally, pursue strategic partnerships with specialized logistics and regional manufacturing partners to offset tariff exposure and to accelerate regional regulatory approvals. These steps, taken together, will improve resilience, lower operational friction, and strengthen the position of stakeholders across the value chain.

Mixed-methods research approach combining primary stakeholder interviews, secondary technical review, and iterative expert validation to ensure rigorous, transparent insights

The research methodology integrates a mixed-methods approach combining primary qualitative interviews, systematic secondary literature review, and technical validation to ensure robust and defensible findings. Primary research included structured interviews with clinical specialists, manufacturing quality leaders, procurement officers, and logistics executives to capture real-world operational constraints, clinical decision drivers, and supplier negotiation dynamics. Secondary sources comprised peer-reviewed clinical literature, regulatory guidance documents, manufacturing best-practice standards, and public clinical program descriptions to contextualize interview insights and corroborate technical assertions.

Data synthesis relied on cross-validation across information streams and iterative expert review to reconcile conflicting inputs. Technical validation of manufacturing and quality assertions was achieved through anonymized supplier disclosures and regulatory inspection summaries. Throughout the process, emphasis was placed on transparency of assumptions, traceability of qualitative inputs, and clarity around limitations, ensuring that conclusions reflect observable industry practice without extrapolating beyond validated evidence.

Strategic conclusion synthesizing clinical importance, operational imperatives, and supply chain resilience considerations for stakeholders engaged with hyperimmune globulin therapies

In summary, hyperimmune globulin injections occupy a strategic niche in modern therapeutic arsenals, delivering targeted passive immunity where specific antibodies provide clinical benefit. The interplay of technological improvements in plasma selection and fractionation, evolving care delivery models that shift administration venues, and regulatory emphasis on traceability are collectively reshaping stakeholder priorities. Supply chain resilience remains central, with tariff changes and regional infrastructure differences reinforcing the need for diversified sourcing, regional manufacturing strategies, and stronger logistics partnerships.

As clinical programs continue to refine indication-specific protocols and as manufacturers invest in quality and analytics, organizations that proactively align operational capability with clinical and payer expectations will achieve more predictable access and better patient outcomes. Ultimately, the path forward favors integrated strategies that combine technical excellence, pragmatic distribution planning, and collaborative engagement with clinical and regulatory stakeholders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hyperimmune Globulin Injection Market, by Indication

  • 8.1. Diphtheria
  • 8.2. Hepatitis B
  • 8.3. Rabies
  • 8.4. Respiratory Syncytial Virus
  • 8.5. Tetanus

9. Hyperimmune Globulin Injection Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous

10. Hyperimmune Globulin Injection Market, by Packaging Type

  • 10.1. Multi Dose Vial
  • 10.2. Single Dose Vial

11. Hyperimmune Globulin Injection Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
  • 11.3. Home Healthcare
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals

12. Hyperimmune Globulin Injection Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Hyperimmune Globulin Injection Market, by Application

  • 13.1. Prophylactic
  • 13.2. Therapeutic

14. Hyperimmune Globulin Injection Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Hyperimmune Globulin Injection Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Hyperimmune Globulin Injection Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Hyperimmune Globulin Injection Market

18. China Hyperimmune Globulin Injection Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. ADMA Biologics
  • 19.6. Baxter International Inc.
  • 19.7. Bharat Serums and Vaccines Limited
  • 19.8. Bio Products Laboratory
  • 19.9. Biotest AG
  • 19.10. China Biologic Products Holdings, Inc.
  • 19.11. CSL Behring
  • 19.12. Emergent BioSolutions
  • 19.13. Green Cross Corporation
  • 19.14. Grifols
  • 19.15. Hualan Biological Engineering Inc.
  • 19.16. Intas Pharmaceuticals Ltd.
  • 19.17. Kamada Pharmaceuticals
  • 19.18. Kedrion Biopharma
  • 19.19. LFB Group
  • 19.20. Octapharma
  • 19.21. Sanquin
  • 19.22. Shanghai RAAS Blood Products Co., Ltd.
  • 19.23. Shire
  • 19.24. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DIPHTHERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY RABIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY RABIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY TETANUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY TETANUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY TETANUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)